February 6, 2019 – Omron Healthcare Inc. and physIQ Inc. announced a collaboration to integrate Omron’s HeartGuide wearable blood pressure monitoring device into the pinpointIQ platform to monitor at-risk patients in an outpatient setting. The strategic collaboration aims to generate actionable clinical information for at-risk patients in an outpatient environment by leveraging the complementary technologies of each company.
The U.S. Food and Drug Administration (FDA)-cleared Omron HeartGuide, which recently announced its retail availability at the 2019 Consumer Electronics Show (CES) and awarded the Engadget “Best of CES” award for best wearable, is a wearable blood pressure monitor made in the convenient form of a wristwatch. It uses oscillometric technology to measure medically-accurate blood pressure readings and monitors activity and sleep. PhysIQ’s pinpointIQ solution is an enterprise-ready, device-agnostic platform designed to capture continuous multivariate physiological data from wearable sensors, apply FDA-cleared artificial intelligence-based analytics, and provide actionable clinical information to a patient’s care team. Collectively, the combined solution represents an opportunity to enable a proactive care delivery model to better support at-risk patients at home.
The initial implementation of the combined solution will be with a major Chicago-area integrated health system and focus on supporting post-discharge patients who have been hospitalized for either heart failure or heart attack. Patients will wear HeartGuide, which will transmit data through the physIQ mobile app to the pinpointIQ cloud-based platform. Clinicians will access patient data and analytics through the pinpointIQ user interface such that they can proactively manage their at-risk patients.
For more information: www.omronhealthcare.com, www.physiq.com
July 16, 2024 
